🏛️ Verified NIH Record • Updated 2026-07-02
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) (NCT06220604)
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Janssen Research & Development, LLC
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Who can join: Review the eligibility criteria below.
Location: Alliance Dermatology and MOHS Center P C — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (128 Sites)
Showing the first 25 of 128 sites.
- Alliance Dermatology and MOHS Center P C — Phoenix, Arizona
- California Dermatology & Clinical Research Institute — Encinitas, California
- T Joseph Raoof Md Inc — Encino, California
- UCSF Fresno — Fresno, California
- University of California Los Angeles - Division of Dermatology — Los Angeles, California
- Wallace Medical Group, Inc — Los Angeles, California
- Dermatologist Medical Group of North County, Inc. — Oceanside, California
- Miami Dermatology And Laser Institute — Miami, Florida
- Bioclinical Research Alliance Inc. — Miami, Florida
- Forcare Clinical Research Inc — Tampa, Florida
- Southeast Dermatology Specialists — Douglasville, Georgia
- Arlington Dermatology — Rolling Meadows, Illinois
- Skin Sciences, PLLC — Louisville, Kentucky
- Qualmedica Research — Owensboro, Kentucky
- DermAssociates, PC — Rockville, Maryland
- Metro Boston Clinical Partners — Brighton, Massachusetts
- ActivMed Practices and Research — Methuen, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- Great Lakes Research Group — Bay City, Michigan
- The Derm Institute of West Michigan — Caledonia, Michigan
- Hamzavi Dermatology — Canton, Michigan
- Somerset Skin Centre — Troy, Michigan
- Cleaver Dermatology — Kirksville, Missouri
- Bexley dermatology research — Bexley, Ohio
- Essential Medical Research — Tulsa, Oklahoma
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Plaque Psoriasis
- A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis — Phoenix, Arizona
- Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis — Phoenix, Arizona
- A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis — Birmingham, Alabama
- Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects — Rogers, Arkansas
- Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis — Birmingham, Alabama
Explore by condition: All Plaque Psoriasis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.